The first time this got near FDA approval, CXS was not going ONLY for approval for patients who had failed (one or two?) other treatments.
Does anyone know how much this affects their potential market sizes compared with the original application?
- Forums
- ASX - By Stock
- cephalon takeover
The first time this got near FDA approval, CXS was not going...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)